Sakar Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹311.45

prior close

₹318.80

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%+1.4% vs market

Pharmaceuticals peers, median of 150sector+0.4%+2.1% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.6

15m

+0.3

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4+1.0+1.4+0.4+2.1

Next day

+0.3+1.8-1.4+0.9-0.6

-0.1+3.0-3.1+2.0-2.0

-0.4+1.9-2.3+1.2-1.6

+1.1+2.7-1.6+1.9-0.8

-0.9+2.6-3.4+2.0-2.9

-1.0+3.8-4.9+1.7-2.8

15d

+0.7+5.7-5.0+2.8-2.1

+3.4+6.7-3.3+2.6+0.8

+11.3+9.6+1.7+4.8+6.5

+4.7+4.6+0.1+0.0+4.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sakar Healthcare's Board approved its audited results for the year ended 31 March 2025. Revenue from operations grew about 16% to Rs. 17,758 lakh (from Rs. 15,335 lakh a year ago). Profit after tax jumped nearly 50% to Rs. 1,750 lakh (vs Rs. 1,167 lakh), with EPS rising to Rs. 7.97 from Rs. 5.64. Operating cash flow strengthened to Rs. 3,403 lakh versus Rs. 2,447 lakh last year, though cash and equivalents on the balance sheet dropped to just Rs. 10 lakh. Statutory auditors J.S. Shah & Co. issued an unmodified (clean) opinion on both standalone and consolidated results.

Likely market impact

Strong earnings growth and clean audit opinion are positive for shareholders. The near-zero cash balance despite healthy operating cash flow is a point to watch, as most cash is being absorbed into capital expenditure and working capital. Overall, results support a constructive view on the stock.